The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The AICVD tool can predict the risk of cardiovascular disease.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery
Medicines, including insulin, to be available in 40 lower-income countries
Younger Indians have a 10 times higher rate of heart attack
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
Subscribe To Our Newsletter & Stay Updated
